Logo do repositório
Tudo no RIUFPA
Documentos
Contato
Sobre
Ajuda
  • Português do Brasil
  • English
  • Español
  • Français
Entrar
Novo usuário? Clique aqui para cadastrar. Esqueceu sua senha?
  1. Início
  2. Pesquisar por Assunto

Navegando por Assunto "Dificuldades Operacionais"

Filtrar resultados informando as primeiras letras
Agora exibindo 1 - 1 de 1
  • Resultados por página
  • Opções de Ordenação
  • Carregando...
    Imagem de Miniatura
    ItemAcesso aberto (Open Access)
    Análise Histórico-Normativa do Fundo de Desenvolvimento da Amazônia
    (Universidade Federal do Pará, 2023-09-19) CORRÊA JÚNIOR, José Roosevelt Araújo; SIMONIAN, Ligia Terezinha Lopes; http://lattes.cnpq.br/6620574987436911; https://orcid.org/0000-0001-6690-7244
    The Amazon Development Fund (FDA) is an important instrument of action of the National Regional Development Policy (PNDR) in the Legal Amazon, being an inducer of large productive enterprises for the region. Some conditions of its system may harm the Fund's attractiveness to credit seekers in the region and financial institutions able to act as operating agents. This work analyzes these conditions from normative, technical and project approval aspects, using data extracted from FDA technical reports prepared by Sudam and technical reports from Condel/SUDAM, PRDA and CGU. With this, the following research problem arises: What aspects have a negative impact on the attractiveness of the FDA? The theoretical framework addresses the main theories on regional development, the main government interventions in terms of development in the Amazon, from the creation of SPVEA and SUDAM in 1966 until their extinction in 2001 and recreation in 2007, in parallel with an analysis of the funds that preceded the creation of the FDA, covering the main aspects of governance and management and the main characteristics that differentiate them. Next, the work analyzes the regulatory history that has guided the FDA's system since its creation, detailing 5 operational difficulties listed based on the report data. As results, the work presents a proposal to increase the remuneration of the operating agent associated with the risk assumed, increase the maximum FDA financing limits, decrease the project contracting period and indicate the establishment of a minimum percentage to be contributed annually by the STN in the FDA.
Logo do RepositórioLogo do Repositório
Nossas Redes:

DSpace software copyright © 2002-2025 LYRASIS

  • Configurações de Cookies
  • Política de Privacidade
  • Termos de Uso
  • Entre em Contato
Brasão UFPA